IMMUNOMIC THERAPEUTICS
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. The company was founded in 2005 and is based in Lancaster, Pennsylvania.
IMMUNOMIC THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2005-01-01
Address:
Lancaster, Pennsylvania, United States
Country:
United States
Website Url:
http://www.immunomix.com
Total Employee:
11+
Status:
Active
Contact:
717-327-1919
Email Addresses:
[email protected]
Total Funding:
75.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Employees Featured
Founder
Investors List
HLB Co
HLB Co investment in Corporate Round - Immunomic Therapeutics
Keiretsu Forum Northwest
Keiretsu Forum Northwest investment in Venture Round - Immunomic Therapeutics
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels investment in Venture Round - Immunomic Therapeutics
Brainchild Holdings
Brainchild Holdings investment in Venture Round - Immunomic Therapeutics
Life Sciences Greenhouse of Pennsylvania
Life Sciences Greenhouse of Pennsylvania investment in Venture Round - Immunomic Therapeutics
Minority Angel Investor Network
Minority Angel Investor Network investment in Venture Round - Immunomic Therapeutics
Key Employee Changes
Official Site Inspections
http://www.immunomix.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
- Host name: 104.21.10.254
- IP address: 104.21.10.254
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Immunomic Therapeutics"
Immunomic Therapeutics - Crunchbase Company …
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. The company was …See details»
Immunomic Therapeutics, Inc. | LinkedIn
Immunomic Therapeutics, Inc. | 3,044 followers on LinkedIn. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | …See details»
Team - Immunomic Therapeutics
Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, …See details»
Immunomic Therapeutics - Overview, News & Similar companies
Aug 24, 2023 Immunomic Therapeutics Announces Presentation on Manufacturing Cell Therapies at Supply Chain and Logistics for Cell Therapy Summit 2023 ROCKVILLE, Md.- …See details»
Immunomic Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Oct 3, 2023 www.immunomix.com. Holding Company | 2005 | Pennsylvania, United States | 10-50 | www.immunomix.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
About IMMUNOMIC THERAPEUTICS | DxMultiomics
IMMUNOMIC THERAPEUTICS | on DxMultiomics. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical-stage biotechnology company pioneering the development of vaccines …See details»
Compensation & Benefits - Immunomic Therapeutics
At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. As a result, we …See details»
Working at Immunomic Therapeutics - Zippia
Find out what it's like to work at Immunomic Therapeutics. See what kind of people work at Immunomic Therapeutics, career paths working at Immunomic Therapeutics, company culture, …See details»
Immunomic Therapeutics Executives and Board Members of …
Dec 9, 2020 Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platfoSee details»
Immunomic Therapeutics Announces Presentation on Nucleic Acid …
Oct 10, 2022 For more information, please visit www.immunomix.com. Contacts. Company: Melissa Kemp [email protected] 301-968-3501 ITI Media: Melody Carey …See details»
Press Release: Immunomic Therapeutics Forms Collaboration with …
Apr 9, 2020 Read the original BusinessWire publication here. ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO, April 09, 2020 — Immunomic Therapeutics, Inc., a privately held …See details»
Immunomic Therapeutics, Inc. (Immunomic Therapeutics, Inc.) - 药 …
Vaccination with LT S220A-UNITE™ DNA vaccine (ITI-3000) induced antigen-specific CD4 T cell responses and a strong humoral response that were sufficient to delay tumor growth of a …See details»
Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical ...
Aug 24, 2023 Immunomic Therapeutics, Inc., a privately held, clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, todSee details»
Careers - Immunomic Therapeutics
Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. We are looking for passionate individuals who want to create leading edge technology, …See details»
immunoFyx
ImmunoFyx is developing novel immuno-therapeutics to reduce the growth, angiogenesis, and metastasis of solid tumors. We specifically target and inhibit a highly expressed cell surface …See details»
ITI Forms Collaboration with EpiVax & PharmaJet to Develop …
Apr 9, 2020 Immunomic will work with leaders from EpiVax and PharmaJet, who have a wealth of immunology and vaccine delivery expertise, to rapidly develop its COVID-19 vaccine.See details»
Bioanalytical and Biomarker Sciences | Immunologix
Nov 15, 2024 Composed of globally recognized thought leaders in bioanalysis, immunogenicity and biomarkers, our team brings a proven track record of influencing industry best practices …See details»
Pipeline - Immunomic Therapeutics
Stemming from our UNITE® Platform, Immunomic Therapeutics has developed a robust pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology …See details»
Oncology - Immunomic Therapeutics
We believe that the UNITE platform has the potential to broaden the current use of cancer immunotherapy by complementing approved and investigational approaches. Preclinical data …See details»